Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTXGet Rating) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

AKTX has been the topic of a number of other research reports. HC Wainwright initiated coverage on Akari Therapeutics in a report on Monday, December 5th. They set a “buy” rating and a $1.50 target price on the stock. Alliance Global Partners began coverage on Akari Therapeutics in a research report on Tuesday, November 1st. They set a “buy” rating and a $4.00 price target on the stock.

Akari Therapeutics Trading Up 2.9 %

Shares of AKTX opened at $0.53 on Friday. Akari Therapeutics has a 1 year low of $0.38 and a 1 year high of $1.61. The stock has a market cap of $39.10 million, a P/E ratio of -1.50 and a beta of 1.32. The stock’s 50-day moving average price is $0.51 and its two-hundred day moving average price is $0.78.

Institutional Investors Weigh In On Akari Therapeutics

Hedge funds have recently modified their holdings of the business. LPL Financial LLC acquired a new stake in Akari Therapeutics in the 2nd quarter valued at approximately $83,000. Omnia Family Wealth LLC raised its position in Akari Therapeutics by 3.2% in the 3rd quarter. Omnia Family Wealth LLC now owns 782,372 shares of the biopharmaceutical company’s stock valued at $493,000 after buying an additional 24,228 shares during the last quarter. Finally, Armistice Capital LLC acquired a new stake in Akari Therapeutics in the 3rd quarter valued at approximately $2,703,000. Institutional investors and hedge funds own 13.59% of the company’s stock.

About Akari Therapeutics

(Get Rating)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.

Read More

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.